德視佳(01846.HK)前兩個月眼科手術總數為4401宗 同比增加約7.2%
格隆匯3月15日丨德視佳(01846.HK)公吿,儘管受到全球範圍內COVID-19疫情反覆的影響,集團於截至2022年2月28日止兩個月進行的眼科手術總數為4401宗,超過集團於2021年同期進行的眼科手術總數(即4106宗眼科手術),增加約7.2%。
截至2022年2月28日止兩個月,集團進行的屈光性激光手術為2229宗,較2021年同期數目(即1950宗屈光性激光手術)增加約14.3%。晶體置換手術為1732宗,較2021年同期數目(即1621宗晶體置換手術)增加約6.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.